Enhanced magnetic hyperthermia using anti-PD-L1 antibody-conjugated magnetoliposomes in a murine subcutaneous bladder cancer model

Read full text Summarise with VIRAT
Authors: Masakazu Gonda, Noriyasu Kawai, Daiki Ishikawa, Maria Aoki, Toshiharu Morikawa, Nobuhiko Shimizu, Takashi Nagai, Toshiki Etani, Taku Naiki, Shuzo Hamamoto, Atsushi Okada, Rintaro Saito
+3 more Masahiro Kaneko, Akira Itô, Takahiro Yasui
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Bladder cancer (BC) often arises in an immunosuppressive tumor microenvironment that limits responses to immune checkpoint inhibitors. Magnetic hyperthermia therapy (MHT) can induce immunogenic cell death, but its value as an immunotherapeutic remains insufficient. We conjugated anti-programmed death-ligand 1 (PD-L1) antibody (αPD-L1) with magnetite cationic liposomes (MCL) and developed αPD-L1@MCL for MHT in an MB49 murine subcutaneous BC model. Mice received a single or triple exposure of αPD-L1@MCL-mediated MHT (P-MHT) at 43 °C or 46 °C (n = 5 per group), then we assessed tumor growth and CD8+ T-cell infiltration. Without αPD-L1, triple MHT at 46 °C induced complete tumor regression, whereas a single exposure 43 °C was insufficient. A single exposure 43 °C P-MHT achieved complete regression in four out of five mice. Flow cytometry revealed an increase in CD8+ T cells in tumors treated with P-MHT. Our αPD-L1@MCL enables hyperthermia with magnetic nanoparticles and immunotherapy with an anti-PD-L1 antibody. These findings support further development of hyperthermia mediated by anti-PD-L1 antibody-conjugated magnetic nanoparticles as a promising therapeutic strategy for BC.

Fields of Study & Subjects

Nanoplatforms for cancer theranostics Ultrasound and Hyperthermia Applications Nanoparticle-Based Drug Delivery

Publication details

Journal / source
Figshare
Publication date
27 March 2026
Language
EN